Accelerating metabolic research

Agilent Technologies and Stemina Biomarker Discovery have announced that Agilent will be providing a liquid chromatography system and quadrupole time-of-flight mass spectrometer to accelerate Stemina's metobolomic research.

Agilent Technologies and Stemina Biomarker Discovery have announced that Agilent will be providing a liquid chromatography system and quadrupole time-of-flight mass spectrometer to accelerate Stemina's metobolomic research. The research team uses metabolomic analysis of stem cells for the discovery of biomarkers for use in drug screening and drug development. Software will also be supplied to help researchers interpret the complex data generated by metabolomics experiments.

"We are pleased to broaden our relationship with Agilent to advance our scientific platform and our discovery of important small molecules involved in developmental toxicity and autism," said Beth Donley, Stemina CEO.

"Metabolomics is a major growth area for us, and the innovative work being done at Stemina is the kind we like to support," said Gustavo Salem, Agilent vice president and general manager, Biological Systems Division. "We've aggressively built an LC–MS portfolio for the life sciences in recent years, and the software provides the crucial ability to visualize biological pathways from the massive and complex data sets generated by metabolomics studies."

For more information on the research company visit www.stemina.com

More information on the products is available at www.agilent.com